| Category | Min Lots | Shares | Amount |
|---|---|---|---|
| Retail (sNII) | 1 | 10 | ₹15,000 |
| HNI / NII | 14 | 140 | ₹2,10,000 |
| bHNI / bNII | 67 | 670 | ₹10,05,000 |
| Category | Sub (×) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 2,15,98,483 (50.00%) | — | ₹323,977.25 Cr |
| NII / HNI (Total) | — | 64,79,546 (15.00%) | — | ₹97,193.19 Cr |
| Retail Investors | — | 1,51,18,939 (35.00%) | — | ₹226,784.09 Cr |
| Total ** | — | 4,31,96,968 (100.00%) | — | ₹6,479,545.22 Cr |
| Metric | 30-June-20 | 31-Mar-20 | 31-Mar-19 |
|---|---|---|---|
| Revenue | 916.29 | 2772.41 | 2129.77 |
| PAT | 313.59 | 772.86 | 451.86 |
| EBITDA | — | — | — |
| Net Worth | — | — | — |
| Total Assets | 4691.27 | 4086.04 | 3523.55 |
| Reserves | — | — | — |
| Borrowings | — | — | — |
Gland Pharma Ltd, the Hyderabad-based company is one of the fastest-growing generic injectable companies. It manufactures a diversified range of high-quality complex injectables. The company offers products like sterile injectables, oncology, and ophthalmics, complex injectables (peptides, suspensions, hormonal products, long-acting injectables), NCE-1s, First-to-File products, etc.
The company follows a B2B model to sell its products in more than 60 countries including the US, Canada, Australia, India, Europe, etc. Leading pharma companies i.e. Sagent Pharmaceuticals, Apotex Inc. Athnex Pharmaceutical Division, LLC, Fresenius Kabi USA, LLC, etc. are some of the key customers.
It has 7 robust manufacturing units in India comprising 4 finished formulations facilities, 22 production lines, and 3 APIs.
Company Strengths